Most Read

  1. Pneumococcal Vaccine as One of the Immunization Coverage Targets for Adulthood Vaccines: A Consensus Report of the Study Group for Adult Immunization of the Turkish Society of Clinical Microbiology and Infectious Diseases
  2. Does Hepatitis B Affect Erectile Dysfunction and Lower Urinary Tract Symptoms?
  3. HIV Infection in Turkey: How Close Are We to the Target?
  4. Evaluation of HBeAg-Negative Chronic Hepatitis B Patients Who Had Undergone Liver Biopsy in Accordance With the Guidelines
  5. Diagnosis, Treatment and Prevention of Diabetic Foot Wounds and Infections: Turkish Consensus Report
  6. When to Stop Antiviral Therapy in Chronic Hepatitis B
  7. Mycoplasma hominis and Ureaplasma urealyticum: Their Role in Urogenital System Infections and Retrospective Evaluation of Antibiotic Resistance Rates
  8. Crimean-Congo Haemorrhagic Fever: Treatment and Use of Ribavirin
  9. Modern Diagnostic Methods Used in Bacteriology: Rapid and Effective
  10. A Case of Generalized Tetanus With a Short Incubation Period
  11. Analysis of HIV/AIDS-Related Stigma and Discrimination in Turkey: Results of the People Living With HIV Stigma Index
  12. Does Anti-HIV Positivity in Pregnancy Suggest the Requirement of HIV Prophylaxis for Newborn?

Volume 34, Issue 1

Original Article

Evaluation of Hepatitis B Seroprevalence and Hepatitis B Reactivation Frequency in Rheumatology Patients Using Biological Drug Therapy

Koray Ayar
Affiliations
  • Sağlık Bilimleri Üniversitesi, Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi, Romatoloji Kliniği, Bursa, Türkiye
https://orcid.org/0000-0002-8798-4828
,
Ali Asan
Affiliations
  • Sağlık Bilimleri Üniversitesi Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi, İnfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Kliniği, Bursa, Türkiye
https://orcid.org/0000-0002-8856-7356
,
Tülay Dilara Hattatoğlu
Affiliations
  • Sağlık Bilimleri Üniversitesi, Bursa Yüksek İhtisas Eğitim ve Araştırma Hastanesi, İç Hastalıkları Kliniği, Bursa, Türkiye
https://orcid.org/0000-0002-8629-4040
  • Biological therapy
  • Hepatitis B
  • reactivation

Abstract

Objective: The presence of hepatitis B virus (HBV) infection in patients using biological drug therapy may cause reactivation. There is insufficient data on the frequency of HBV reactivation, especially after the use of new biological drugs such as tofacitinib, tocilizumab, and secukinumab. This study aims to examine HBV seroprevalence in rheumatology patients using biological drug therapy and investigate the frequency of reactivation in patients with previous HBV infection.

Methods: The charts of 275 patients who were followed up in the rheumatology department and used biological drug therapy were examined to evaluate the HBsAg, anti-HBc IgG, and anti-HBs test results. The frequency of reactivation was investigated by examining the HBV DNA test results before and after the biological drug therapy and the alanin aminotransferase test results were checked throughout the biological drug therapy in anti-HBc IgG-positive patients.

Results: Among the patients, HBsAg was positive in 0.4%, anti-HBs in 34.4%, and anti-HBc IgG in 25.1%. The reactivation frequency was investigated in 53 biological drug therapies applied in 41 patients. The use of prophylactic antiviral drugs, where reactivation was evaluated, was found as 28.6% in TNF inhibitors, 100% in rituximab, 75.0% in tofacitinib, 0% in tocilizumab, 50% in abatacept, and 0% in secukinumab. Reactivation was detected in one of the fifty-three biological drug therapies. The reactivation case was a patient with isolated anti-HBc IgG and initial HBV DNA tests positive, using tocilizumab and cortisone, and not using entecavir prophylactic treatment regularly.

Conclusions: The frequency of previous HBV infection is high in patients using biological therapy. Although prophylactic antiviral drug therapy for HBV has not been used frequently during the use of biological drug therapies other than rituximab in anti-HBc IgG positive patients, reactivation is rare. The risk of reactivation may be low in those receiving tofacitinib and secukinumab therapy and high in those receiving tocilizumab therapy.

  • 42-9
  • Koray Ayar
  • [email protected]
  • 10.36519/kd.2021.08
  • August 28, 2020
  • January 26, 2021
  • 20210430

  • Ayar K, Asan A, Hattatoğlu TD. [Evaluation of hepatitis B seroprevalence and hepatitis B reactivation frequency in rheumatology patients using biological drug therapy]. Klimik Derg. 2021; 34(1): 42-9. Turkish.
  • 627
  • 289
Download as PDF
  • This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. CC BY-NC
Volume 37, Issue 3 Volume 37, Issue 2 Volume 37, Issue 1 Volume 36, Issue 4 Volume 36, Supplement 1 Volume 36, Issue 3 Volume 36, Issue 2 Volume 36, Issue 1 Volume 35, Issue 4 Volume 35, Issue 3 Volume 35, Issue 2 Volume 35, Issue 1 Volume 34, Issue 3 Volume 34, Issue 2 Volume 34, Issue 1 Volume 33, Issue 3 Volume 33, Issue 2 Volume 33, Issue 1 Volume 32, Issue 3 Volume 32, Supplement 1 Volume 32, Supplement 2 Volume 32, Issue 2 Volume 32, Issue 1 Volume 31, Issue 3 Volume 31, Issue 2 Volume 31, Supplement 1 Volume 31, Issue 1 Volume 30, Issue 3 Volume 30, Issue 2 Volume 30, Supplement 1 Volume 30, Issue 1 Volume 29, Issue 3 Volume 29, Issue 2 Volume 29, Issue 1 Volume 28, Supplement 1 Volume 28, Issue 3 Volume 28, Issue 2 Volume 28, Issue 1 Volume 27, Supplement 1 Volume 27, Issue 3 Volume 27, Issue 2 Volume 27, Issue 1 Volume 26, Issue 3 Volume 26, Supplement 1 Volume 26, Issue 2 Volume 26, Issue 1 Volume 25, Issue 3 Volume 25, Issue 2 Volume 25, Issue 1 Volume 24, Issue 3 Volume 24, Issue 2 Volume 24, Issue 1 Volume 23, Issue 3 Volume 23, Issue 2 Volume 23, Issue 1 Volume 22, Issue 3 Volume 22, Issue 2 Volume 22, Issue 1 Volume 21, Issue 3 Volume 21, Supplement 2 Volume 21, Supplement 1 Volume 21, Issue 2 Volume 21, Issue 1 Volume 20, Issue 3 Volume 20, Supplement 2 Volume 20, Issue 2 Volume 20, Issue 1 Volume 20, Supplement 1 Volume 19, Issue 3 Volume 19, Issue 2 Volume 19, Issue 1 Volume 18, Issue 3 Volume 18, Supplement 1 Volume 18, Issue 2 Volume 18, Issue 1 Volume 17, Issue 3 Volume 17, Issue 2 Volume 17, Issue 1 Volume 16, Issue 3 Volume 16, Issue 2 Volume 16, Issue 1 Volume 1, Supplement 1 Volume 15, Issue 3 Volume 15, Issue 2 Volume 15, Issue 1 Volume 14, Issue 3 Volume 14, Issue 2 Volume 14, Issue 1 Volume 13, Issue 3 Volume 13, Issue 2 Volume 13, Supplement 1 Volume 13, Issue 1 Volume 12, Issue 3 Volume 12, Issue 2 Volume 12, Issue 1 Volume 11, Issue 3 Volume 11, Issue 2 Volume 11, Supplement 1 Volume 11, Issue 1 Volume 10, Issue 3 Volume 10, Issue 2 Volume 10, Issue 1 Volume 9, Issue 3 Volume 9, Issue 2 Volume 9, Issue 1 Volume 8, Issue 3 Volume 8, Issue 2 Volume 8, Issue 1 Volume 6, Issue 3 Volume 7, Issue 1 Volume 7, Issue 2 Volume 7, Issue 3 Volume 4, Issue 3 Volume 5, Issue 1 Volume 5, Issue 2 Volume 5, Issue 3 Volume 6, Issue 1 Volume 6, Issue 2 Volume 3, Issue 1 Volume 3, Issue 2 Volume 3, Issue 3 Volume 4, Issue 1 Volume 4, Issue 2 Volume 1, Issue 2 Volume 2, Issue 1 Volume 2, Issue 2 Volume 2, Issue 3 Volume 1, Issue 1